October 14, 2026

Russell Reconstitution Now Happens Twice a Year. What Does That Mean for Public Biotechs?

For decades, public biotechs only had to think seriously about Russell Reconstitution once a year.

Not anymore.

Beginning in 2026, FTSE Russell has moved the Russell U.S. Indexes – including the Russell 1000^®, Russell 2000^® and Russell 3000^® – from an annual reconstitution to a semi-annual reconstitution, taking place in June and December.

That may sound like a relatively minor administrative change. It isn’t.

For hundreds of Nasdaq- and NYSE-listed biotechs, it effectively creates two opportunities – and two risks – every year to move into, out of, or between some of the most widely followed stock indexes in the world.

And in a sector where market capitalizations can move dramatically following a single clinical data readout, FDA decision or financing, six months can be a very long time.

What changed?

Historically, “Russell Recon” happened once a year. Companies were ranked by market capitalization at the end of April, preliminary changes were announced in May, and the newly constituted indexes became effective in late June.

Starting in 2026, FTSE Russell is doing the exercise again six months later.

For the inaugural December reconstitution, the important date is October 30, 2026 – that is “Rank Day.” FTSE Russell will essentially take a snapshot of the eligible U.S. equity market at the close of trading that day.

Preliminary additions and deletions will then be published on November 13, with the new indexes becoming effective after the market closes on December 11. Markets therefore open on December 14 with the newly reconstituted indexes.

Why does this matter for public biotechs?

Because Russell membership is ultimately driven by rules rather than somebody sitting in a room deciding which companies they like.

Eligible U.S. companies are ranked primarily according to their total market capitalization.

Broadly speaking:

• Russell 1000 = the largest 1,000 U.S. companies.
• Russell 2000 = the next 2,000.
• Russell 3000 = the two combined.

There are additional eligibility requirements, of course. Among other things, securities must trade on an eligible U.S. exchange. These currently include Nasdaq, NYSE, NYSE American, NYSE Arca and Cboe.

But for most U.S.-listed biotechs, market capitalization is the variable that management teams can watch most easily. And now they need to watch it twice a year.

Why can index inclusion matter?

Because an extraordinary amount of money follows Russell indexes.

More than $11 trillion in assets are benchmarked against the Russell U.S. Indexes.

When a biotech enters an index, passive funds tracking that index need exposure to it. When it leaves, those same funds may need to sell. That can translate into very substantial trading.

At the June 2026 reconstitution, an extraordinary $219.9 billion of U.S. stocks traded in the closing moments on the NYSE and $334.0 billion on Nasdaq.

That is more than half a trillion dollars.

For smaller biotechs, where average daily trading volumes can be relatively modest, index-related buying or selling can be particularly meaningful. Russell Recon is therefore anything but an academic exercise.

What about moving between the Russell 2000 and Russell 1000?

This is particularly interesting for successful emerging biotech companies.

In June 2026, the market-cap breakpoint between the Russell 1000 and Russell 2000 was approximately $5.7 billion. But crossing $5.7 billion did not automatically mean that a Russell 2000 biotech was promoted.

This is because FTSE Russell uses banding around the breakpoint to reduce unnecessary turnover.

The band around the Russell 1000/2000 breakpoint is ±2.5% of cumulative market capitalization.

Consequently, an existing Russell 1000 company can fall below the nominal breakpoint and remain in the Russell 1000. Likewise, a Russell 2000 company can rise above the nominal breakpoint and remain in the Russell 2000.

Indeed, at the June 2026 reconstitution, 97 Russell 2000 companies ranked above the Russell 1000 breakpoint but remained in the Russell 2000 because of banding.

So simply looking at the smallest company currently in the Russell 1000 and assuming that exceeding its market capitalization guarantees promotion is wrong.

What should biotech IR teams do?

First, put October 30 in the calendar alongside the traditional April “Rank Day.”

Second, monitor your company’s market capitalization relative not simply to the Russell 1000/2000 breakpoint, but also to the banding range surrounding it.

Third, overlay the Russell calendar with your clinical, regulatory and corporate calendar. For a biotech expecting pivotal data or an FDA decision shortly before Rank Day, the potential implications can be significant.

And finally, remember that December is now a genuine reconstitution – not simply another quarterly rebalance.

The annual Russell Recon has effectively become Russell Recon Season One and Russell Recon Season Two.